共 10 条
- [1] Retarding progression of chronic renal disease:the neglected issue of residual proteinuria. Ruggenenti P,Perna A,Remuzzi G,GISEN Group Investigators. Kidney International . 2003
- [2] ACE inhibition re-duces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Remuzzi A,Gagliardini E,Sangalli F,et al. Kidney International . 2006
- [3] Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Bakris GL,Weir MR,Secic M,et al. Kidney International . 2004
- [4] An extremely high dose of losartan affords superior renoprotection in the remnant model. Fujihara CK,Velho M,Malheiros DM,et al. Kidney International . 2005
- [5] Combination treatment of angiotensin-Ⅱreceptor blocker and angiotensin-converting-enzymeinhibitor in non-diabetic renal disease(COOPERATE):a random-ised controlled trial. Nakao N,Yoshimura A,Morita H,et al. The Lancet . 2003
- [6] Progression versus regression of chronic kidney disease. Fogo AB. Nephrology Dialysis Transplantation . 2006
- [7] The seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure:the JNC7report. Chobanian AV,Bakris GL,Black HR,et al. The Journal of The American Medical Association . 2003
- [8] Is it the agent or theblood pressure level that matters for renal protection in chronic ne-phropathies?. Locatelli F,Vecchio LD,D Amico M,et al. Journal of the American Society of Nephrology . 2002
- [9] Progression of chronic kid-ney disease:the role of blood pressure control,proteinuria,and an-giotensin-converting enzyme inhibition:a patient-level meta-analy-sis. Jafar TH,Stark PC,Schmid CH,et al. Annals of Internal Medicine . 2003
- [10] Effects of losartan on renal and cardiovascular outcomes in patients with type2diabetes and nephropathy. Brenner BM,Cooper ME,de Zeeuw D,et al. The New England Journal of Medicine . 2001